Needham Rates Neumora Therapeutics (NMRA) buy, $5 Price Target

Needham Maintains Bullish View on Neumora Therapeutics

Needham analyst Ami Fadia reaffirmed a Buy rating on Neumora Therapeutics (NasdaqGS: NMRA) on June 16, 2026. The firm set a price target of $5.00 for the biotechnology company. This reiteration comes as Neumora continues to develop its pipeline of treatments for brain diseases and neuropsychiatric disorders. The analyst's target reflects a confident outlook on the company's clinical progress, particularly with its lead drug candidates.

This call from Needham aligns with a broader sense of optimism from the analyst community, though it is slightly more conservative than the average Wall Street target. The consensus among the seven analysts covering the stock is currently a Buy, with an average price target of $6.14. The targets for Neumora range from a low of $3.00 to a high of $14.00, placing Needham's $5.00 valuation toward the lower end of the bullish spectrum.

Analysts Set New Price Targets

Other firms have also been keeping a close watch on Neumora's development. On July 13, 2026, RBC Capital maintained an Outperform rating on the stock. However, RBC Capital did lower its price target from $7.00 to $5.00. This adjustment brings RBC's expectations in line with Needham's current $5.00 target. These ratings suggest that while some firms are tempering their near-term price expectations, the fundamental belief in the company's clinical path remains intact.

Neumora Stock Performance and Financial Position

Neumora Therapeutics shares were trading at $0.91 on Tuesday. The stock has faced a difficult period in the market, currently sitting much closer to its 52-week low of $0.68 than its high of $3.65. The company's shares are also trading significantly below their 50-day moving average of $1.44 and their 200-day moving average of $1.99. This technical position shows the stock has been under steady pressure over the last several months.

Financially, Neumora is in a typical position for a clinical-stage biotech firm. It is not yet profitable, reporting a loss of $1.23 per share. Because it has no earnings, the company doesn't have a meaningful P/E ratio. However, it does maintain a healthy current ratio of 4.49, which suggests it has enough cash and short-term assets to cover its immediate bills as it continues its research and development efforts. The company's next earnings report is expected on November 5, 2026.

Focus on Brain Health Treatments

Neumora Therapeutics is a Watertown, Massachusetts-based company that focuses on some of the most challenging areas of medicine. They are developing navacaprant, an oral drug currently in Phase 3 trials for major depressive disorder. They also have programs targeting agitation associated with Alzheimer's disease and schizophrenia. Because the company is still in the testing phase for these drugs, its value is largely tied to whether these clinical trials succeed or fail.

Investors will likely keep a close eye on the upcoming November earnings report and any updates regarding the Phase 3 clinical trials. While analyst ratings provide a glimpse into professional expectations, they are opinions based on current data and not a guarantee of future stock performance. The high volatility often seen in biotech stocks means that clinical trial results can shift these analyst targets quickly.